Tracking motor impairments in the progression of Huntington's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 311-319

  Long, Jeffery D ^a,b   Paulsen, Jane S ^a,c   Marder, Karen ^d,y   Zhang, Ying ^b   Kim, Ji In ^a   Mills, James A ^a   Cross, Stephen ^b   Ryan, Patricia ^b   Epping, Eric A ^a   Vik, Stacie ^b   Chiu, Edmond ^e   Preston, Joy ^e   Goh, Anita ^e   Antonopoulos, Stephanie ^e   Loi, Samantha ^e   Chua, Phyllis ^e   Komiti, Angela ^e   Raymond, Lynn ^f   Decolongon, Joji ^f   Fan, Mannie ^f   Coleman, Allison ^f   Ross, Christopher A ^a   Varvaris, Mark ^g   Yoritomo, Nadine ^g   Mallonee, William M ^a   Suter, Greg ^h   Samii, Ali ⁱ   Macaraeg, Alma ⁱ   Jones, Randi ^j   Wood Siverio, Cathy ^a   Factor, Stewart A ^a   Barker, Roger A ^a   Mason, Sarah ^k   Guzman, Natalie Valle ^k   McCusker, Elizabeth ^l   Griffith, Jane ^l   Loy, Clement ^l   Gunn, David ^l   Orth, Michael ^m   Sübmuth, Sigurd ^m   Barth, Katrin ^m   Trautmann, Sonja ^m   Schwenk, Daniela ^m   Eschenbach, Carolin ^m   Quaid, Kimberly ⁿ   Wesson, Melissa ⁿ   Wojcieszek, Joanne ⁿ   Guttman, Mark ^o   Sheinberg, Alanna ^o   Law, Albie ^o   Perlman, Susan ^p   Clemente, Brian ^p   Geschwind, Michael D ^a   Sha, Sharon ^q   Satris, Gabriela ^q   Warner, Tom ^r   Burrows, Maggie ^r   Rosser, Anne ^s   Price, Kathy ^s   Hunt, Sarah ^s   Marshall, Frederick ^t   Chesire, Amy ^t   Wodarski, Mary ^t   Hickey, Charlyne ^t   Panegyres, Peter ^u   Lee, Joseph ^u   Tedesco, Maria ^u   Maxwell, Brenton ^u   Perlmutter, Joel ^v   Barton, Stacey ^v   Smith, Shineeka ^v   Miedzybrodzka, Zosia ^w   Rae, Daniela ^w   D'Alessandro, Mariella ^w   Craufurd, David ^x   Bek, Judith ^x   Howard, Elizabeth ^x   Mazzoni, Pietro ^y   Wasserman, Paula ^y   Kumar, Rajeev ^z   Erickson, Diane ^z   Nickels, Breanna ^z   Wheelock, Vicki ^aa   Kjer, Lisa ^aa   Martin, Amanda ^aa   Farias, Sarah ^aa   Martin, Wayne ^ab   King, Pamela ^ab   Wieler, Marguerite ^ab   Sran, Satwinder ^ab   Suchowersky, Oksana ^ac   Ahmed, Anwar ^ac   Rao, Stephen ^ac   Reece, Christine ^ac   Bura, Alex ^ac   Mourany, Lyla ^ac   Pallai, Jagan ^ac   more..

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c E11 SSH   (United States)

^d Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Hereditary Neurological Disease Centre   (United States)

ⁱ VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^l WESTMEAD HOSPITAL   (Australia)

^m UNIVERSITY OF ULM   (Germany)

ⁿ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF TORONTO   (Canada)

^p UCLA MEDICAL CENTER   (United States)

^q UNIVERSITY OF CALIFORNIA   (United States)

^r NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^s CARDIFF UNIVERSITY   (United Kingdom)

^t UNIVERSITY OF ROCHESTER   (United States)

^u Graylands Selby Lemnos and Special Care Health Services   (Australia)

^v WASHINGTON UNIVERSITY   (United States)

^w Clinical Genetics Centre   (United Kingdom)

^x UNIVERSITY OF MANCHESTER   (United Kingdom)

^y NewYork Presbyterian Hospital   (United States)

^z Clinical Genetics Centre ^*  (United States)

^aa UNIVERSITY OF CALIFORNIA   (United States)

^ab UNIVERSITY OF ALBERTA   (Canada)

^ac LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

Cohort studies; Huntington's disease; Movement disorders; Neurodegenerative disease; Predictive testing

Indexed keywords

ADULT; ARTICLE; CAG REPEAT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC CONFIDENCE LEVEL; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; ILLNESS TRAJECTORY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PREDICTION; PRIORITY JOURNAL; PRODROMAL SYMPTOM; SAMPLE SIZE; UNIFIED HUNTINGTON DISEASE RATING SCALE; AGED; GENETIC PREDISPOSITION; GENETICS; HUNTINGTON DISEASE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROPSYCHOLOGICAL TEST; PROCEDURES; STATISTICAL MODEL;

ADULT; AGED; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; HUNTINGTON DISEASE; LINEAR MODELS; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROPSYCHOLOGICAL TESTS;

EID: 84896125995     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25657     Document Type: Article

References (37)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the PREDICT-HD Study. J Neurol Neurosurg Psychiatry 2008;79:874-880.
3. Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin Pharmacother 2007;8:141-153.
4. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
5. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and-consistency. Mov Disord 1996;11:136-142.
6. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
7. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-epa in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005;65:286-292.
8. Solomon AC, Stout JC, Weaver M, et al. Ten year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord 2008;23:1830-1836.
9. Witjes-Ane MN, Mertens B, van Vugt JP, Bachoud-Levi AC, van Ommen GJ, Roos RA. Longitudinal evaluation of "presymptomatic" carriers of Huntington's disease. J Neuropsychiatry Clin Neurosci 2007;19:310-317.
10. Meyer C, Landwehrmeyer B, Schwenke C, et al. Rate of change in early Huntington's disease: a clinicometric analysis. Mov Disord 2012;27:118-124.
11. Kirkwood SC, Su JL, Conneally P, et al. Progression of symptoms in the early and middle stages of Huntington disease. Arch Neurol 2001;58:273-278.
12. Mahant N, McCusker EA, Byth K, et al. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092.
13. Siesling S, van Vugt JP, Zwinderman KA, et al. Unified Huntington's Disease Rating Scale: a follow-up. Mov Disord 1998;13:915-919.
14. Paulsen JS, Hayden M, Stout JC, et al. Preparing for preventive clinical trials: the PREDICT-HD Study. Arch Neurol 2006;63:883-890.
15. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2002.
16. Langbehn DR, Hayden MR, Paulsen JS, et al. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010;153B:397-408.
17. Lee JM, Ramos EM, Lee JH, et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 2012;78:690-695.
18. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-Plus. New York: Springer; 2000.
19. Long JD. Longitudinal Data Analysis for the Behavioral Sciences Using R. Thousand Oaks, CA: Sage Publications Inc.; 2012.
20. Zhang Y, Long JD, Mills JA, et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:751-763.
21. Penney JJB, Vonsattel JP, MacDonald ME, et al. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
22. Tabrizi SJ, Reilmann R, Roos RAC, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the Track-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
23. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-1020.
24. Rosenblatt A, Kumar BV, Mo A, et al. Age, CAG repeat length, and clinical progression in Huntington's disease. Mov Disord 2012;27:272-276.
25. Ravina B, Romer M, Constantinescu R, et al. The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord 2008;23:1223-1227.
26. Stout JC, Weaver M, Solomon AC, et al. Are cognitive changes progressive in prediagnostic HD? Cogn Behav Neurol 2007;20:212-218.
27. Reedeker N, Mast RCVD, Giltay EJ, et al. Hypokinesia in Huntington's disease co-occurs with cognitive and global dysfunctioning. Mov Disord 2010;25:1612-1618.
28. Blekher T, Johnson SA, Marshall J, et al. Saccades in presymptomatic and early stages of Huntington disease. Neurology 2006;67:394-399.
29. Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol 2007;64:116-121.
30. Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2002;30:83-103.
31. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
32. Vaccarino AL, Anderson K, Borowsky B, et al. An item response analysis of the motor and behavioral subscales of the Unified Huntington's Disease Rating Scale in Huntington disease gene expansion carriers. Mov Disord 2011;26:877-884.
33. Gallbraith S, Marschner IC. Guidelines for the design of clinical trials with longitudinal outcomes. Control Clin Trials 2002; 23(3):257-273.
34. Yi Q, Panzarella T. Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model. Control Clin Trials 2002;23:481-496.
35. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
36. Armstrong MJ, Miyasaki JM, American Academy of Neurololgy. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
37. Altmann DR, Jasperse B, Barkhof F, et al. Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 2009;72:595-601.